Greenland Mines Ltd (NASDAQ: GRML) announced that IP Australia has granted Australian Patent No. 2023252508, covering gene therapy technology exclusively licensed by the company’s Biotech Division. The patent protects the expression of the human Klotho protein for the treatment of neuromuscular diseases, including amyotrophic lateral sclerosis (ALS).
The patent strengthens the intellectual property portfolio supporting Greenland Mines’ Klotho-based therapeutic platform. It includes claims covering gene therapy constructs, neuronal and induced pluripotent stem cells, and viral and non-viral delivery systems. The company noted that the patent further supports the development of its KLTO-202 program, which targets ALS and other neuromuscular disorders.
This development is significant for Greenland Mines as it advances its biotech division alongside its mining operations. The company operates two divisions: Mining, focused on exploration and development of the Skaergaard Project in southeast Greenland and the Sarfartoq neodymium-praseodymium rare earths project in southwest Greenland; and Biotech, which includes the KLTO-202 program for ALS. The company’s strategy is to build a multi-asset platform with exposure to rare earth magnet materials, precious metals, and midstream processing opportunities, while advancing its North Atlantic Critical Metals Corridor vision.
The patent grant adds to Greenland Mines’ intellectual property in gene therapy, a field with potential for treating devastating neuromuscular conditions. ALS, a progressive neurodegenerative disease, currently has limited treatment options, making new therapeutic approaches highly sought after. The Klotho protein has been studied for its potential roles in aging and neuroprotection, and its expression via gene therapy could offer a novel treatment pathway.
For more details, the full press release is available at https://nnw.fm/PVbbH. Additional news and updates relating to GRML can be found in the company’s newsroom at https://nnw.fm/GRML.
